Single-molecule detections at point-of-care: is this a dream?

Jan 23 2025

Join Luisa Torsi as she discusses single-molecule detections at point-of-care during her webinar.

Webinar date: 13 February
Time: 7-8 PM GMT
Presented by: Luisa Torsi
Sign up HERE>>

Imagine a future where diseases can be detected at their earliest stages, even before symptoms appear.

This is no longer a dream but a revolutionary step forward in healthcare. And it's made possible by the groundbreaking SiMoT (Single-Molecule-with-a-large-Transistor) bioelectronic platform.

Join us for this insightful webinar to discover how this technology is set to transform diagnostics.

A new era in early disease detection

Detecting diseases in asymptomatic individuals is a game-changer. It enables timely interventions and significantly improving patient outcomes.

The SiMoT platform aligns with the World Health Organization’s benchmarks for point-of-care testing (POCT), offering unparalleled sensitivity and specificity in a portable, cost-effective format.

As part of the SiMBiT project, SiMoT is capable of detecting both protein and DNA single markers in just 0.1 mL of biological fluid.

This level of precision makes it an ideal tool for early disease screening, even in individuals showing no symptoms.

Unmatched diagnostic performance

SiMoT offers diagnostic accuracy on par with molecular tests, achieving an impressive 96-99% sensitivity and specificity.

This exceptional performance was demonstrated in a pre-clinical trial for pancreatic cancer. No false negatives were reported among more than 70 patients.

Such results highlight the potential of SiMoT to revolutionize early disease detection.

Real-world applications and clinical trials

The SiMoT platform is undergoing rigorous evaluation in an in-vivo diagnostic clinical trial involving 1,500 assays of blood and urine samples from oncology patients.

This trial aims to advance the technology from TRL5 to TRL7, bringing it closer to widespread clinical adoption.

Additionally, the SiMBiT project’s development of a 96-bioelectronic sensor array for multiplexed detection has been validated in clinical trials for early cancer screening, further demonstrating its potential.